NCT04723316

Tumour Characterisation to Guide Experimental Targeted Therapy - National

Recruiting now Last updated 7 February 2024

What this trial tests

trial in Cancer in 6,000 participants. Currently enrolling.

Timeline

30 June 2021

Primary endpoint
30 January 2026

30 January 2028

Quick facts

Lead sponsor	The Christie NHS Foundation Trust
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	6,000
Start date	30 June 2021
Primary completion	30 January 2026
Estimated completion	30 January 2028
Sites	20 locations across United Kingdom

Conditions studied

• Cancer — all drugs for Cancer →

Sponsor

The Christie NHS Foundation Trust

Who can join

16 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary aim of TARGET National is to establish a national framework to offer molecular profiling of circulating tumour DNA and/or tumour tissue (optional) to patients with advanced solid cancers referred to any of the Experimental Cancer Medicine Centres (ECMCs) across the UK, in order to help decision making for allocation to molecularly targeted experimental cancer treatments. Patients will be allocated treatment using a national Molecular Tumour Board to find the most suited therapies based on their molecular profiling results.

This study aims to recruit up to 6,000 patients with advanced solid tumours across 5 years and proposes to collect blood samples, archival tumour tissue and fresh tissue (optional)

The data may also be used for future development of predictive cancer biological markers, the design of clinical trials involving new or existing drugs, discovery of new genetic targets and exploring how resistance to specific anticancer agents arises in patients to help improve future cancer treatment management.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine.
   Derouane F, van Marcke C, Berlière M, Gerday A, et al · · 2022 · cited 54× · PMID 36010869 · DOI 10.3390/cancers14163876
2. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
   Pamarthy S, Sabaawy HE. · · 2021 · cited 44× · PMID 34587953 · DOI 10.1186/s12943-021-01426-3
3. Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research.
   Waseem M, Wang BD. · · 2024 · cited 15× · PMID 38256166 · DOI 10.3390/ijms25021093
4. Patient-derived organoids for precision oncology: a platform to facilitate clinical decision making.
   Chitrangi S, Vaity P, Jamdar A, Bhatt S. · · 2023 · cited 12× · PMID 37479967 · DOI 10.1186/s12885-023-11078-9
5. Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial.
   Marchetti P, Curigliano G, Biffoni M, Lonardi S, et al · · 2025 · cited 11× · PMID 41023484 · DOI 10.1038/s41591-025-03918-x
6. Heterogeneity in precision oncology.
   Tomasik B, Garbicz F, Braun M, Bieńkowski M, et al · · 2024 · cited 4× · PMID 38549846 · DOI 10.1017/pcm.2023.23
7. Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patients.
   Herrero Colomina J, Johnston E, Duffus K, Zaïr ZM, et al · · 2025 · cited 3× · PMID 40133697 · DOI 10.1038/s41698-025-00863-3
8. Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders.
   Rae S, Plummer E, Fitzgerald L, Hogarth L, et al · · 2023 · cited 1× · PMID 37702806 · DOI 10.1007/s00432-023-05365-y